STUDY OF MEDTRONIC'S ADAPTA PACEMAKER BEGINS

Medtronic announced the start of a clinical study to evaluate its Adapta pacemaker, designed to promote natural heart activity for patients with slow heart rhythms.

The clinical study is a prospective, non-randomized, multicenter trial that will enroll up to 120 patients at 10 sites to evaluate the safety and clinical performance of the Adapta system. The pacemaker incorporates Medtronic's pacing mode (called "managed ventricular pacing"), enabling users to program the device to deliver pacing pulses to the heart's ventricle only when necessary.

Within the next year, Medtronic expects to introduce a portfolio of fully automatic pacemakers - the Adapta, Versa and Sensia - in regions worldwide. These systems are designed to provide physiologic pacing adapted to the needs of individual patients.